BE’s Michael Mitchell Wins Controlled Release Society T. Nagai Award

Michael Mitchell, Ph.D.

Michael Mitchell, Skirkanich Assistant Professor of Innovation in the Department of Bioengineering, is the recipient of the Controlled Release Society (CRS) 2019 T. Nagai Postdoctoral Research Achievement Award, which comes with a $3,000 honorarium.

According to the CRS website, “The Controlled Release Society T. Nagai Postdoctoral Research Achievement Award has been established to recognize an individual postdoctoral candidate who has recently completed outstanding postdoctoral research in controlled release science and technology, and the postdoc’s advisor who played an integral role in those achievements.”

Mitchell and his postdoctoral advisor at MIT, Robert Langer, will receive the award at the 2019 CRS annual meeting this July in Valencia, Spain.

The sole recipient of this award, Mitchell was recognized for his work on engineering controlled release technologies for cancer gene therapy and immunotherapy. Mitchell focuses on improving the way drugs are delivered within the body by combining approaches from engineering, biology, machine learning, and data science to better target diseased cells. Mitchell’s work helps to lay the foundation for a new class of therapeutic strategies against hematologic cancers such as multiple myeloma and leukemia.

For this research, Mitchell also received the Burroughs Wellcome Fund Career Award at the Scientific Interface in 2016, the NIH Director’s New Innovator Award in 2018, and a Rising Star Award in Cellular and Molecular Bioengineering from the Biomedical Engineering Society in 2019. He joined the Penn faculty in January 2018 after completing an NIH NCI postdoctoral fellowship at the Koch Institute for Integrative Cancer Research at MIT.

Originally posted on the Penn Engineering Medium blog. Media contacts Evan Lerner. 

Michael Mitchell Receives BMES Rising Star Award

Michael Mitchell, PhD, Skirkanich Assistant Professor of Innovation in the Department of Bioengineering at Penn, has been honored with a Rising Star Award in Cellular and Molecular Bioengineering from the Biomedical Engineering Society (BMES). According to the BMES website, “The BMES Cellular and Molecular Bioengineering Special Interest Group brings together researchers with diverse scientific and clinical interests with a common goal of understanding and engineering molecules, cells, their interactions and microenvironments in the pursuit of controlling biological processes and improving the practice of medicine.” Dr. Mitchell received the award and delivered a lecture at the 2019 Cellular and Molecular Bioengineering Conference in San Diego, California in January, 2019.

One of six early-stage investigators from across the nation to receive the honor, Dr. Mitchell was recognized for his work on engineering delivery technologies for cancer gene therapy and immunotherapy, which is helping to lay the foundation for a new class of therapeutic strategies against hematologic cancers such as multiple myeloma and leukemia. In 2018, Dr. Mitchell was awarded the NIH Director’s New Innovator Award for this research, and received the Burroughs Wellcome Fund Career Award at the Scientific Interface) in 2016. He joined the Penn faculty in January 2018 after completing an NIH NCI postdoctoral fellowship with Dr. Robert Langer at the Koch Institute for Integrative Cancer Research at MIT.

Michael Mitchell Receives NIH Director’s New Innovator Award

Michael Mitchell, Skirkanich Assistant Professor of Innovation in Penn Engineering’s Department of Bioengineering, is drawing on a variety of fields — biomaterials engineering, data science, gene therapy and machine learning — to tailor the next generation of drug delivery vehicles with this level of precision.

His work in this field has earned him a $2.4 million NIH Director’s New Innovator Award, which is part of the NIH Common Fund’s High-Risk, High-Reward Research program. The High-Risk, High-Reward Research program supports innovative research proposals that might not prove successful in the conventional peer-review process despite their potential to advance medicine.

Read the full story at Penn Medium.

Oncology/Engineering Review Published

oncology
Mike Mitchell, Ph.D.

Michael Mitchell, Ph.D., who will arrive in the Spring 2018 semester as assistant professor in the Department of Bioengineering, is the first author on a new review published in Nature Reviews Cancer on the topic of engineering and the physical sciences and their contributions to oncology. The review was authored with Rakesh K. Jain, Ph.D., who is Andrew Werk Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School, and Robert Langer, Sc.D., who is Institute Professor in Chemical Engineering at the David H. Koch Institute for Integrative Cancer Research at MIT. Dr. Mitchell is currently in his final semester as a postdoctoral fellow at the Koch Institute and is a member of Dr. Langer’s lab at MIT.

The review focuses on four key areas of development for oncology in recent years: the physical microenvironment of the tumor; technological advances in drug delivery; cellular and molecular imaging; and microfluidics and microfabrication. Asked about the review, Dr. Mitchell said, “We’ve seen exponential growth at the interface of engineering and physical sciences over the last decade, specifically through these advances. These novel tools and technologies have not only advanced our fundamental understanding of the basic biology of cancer but also have accelerated the discovery and translation of new cancer therapeutics.”

New Faculty Joining Penn Bioengineering

We are thrilled to announce the successful recruitment of three (!) new faculty members to the department. We conducted a national faculty search and could not decide on one — we wanted all three of our finalists!  We are very happy that they chose Penn and think we can provide an amazing environment for their education and research programs.

new faculty hughes
Alex Hughes, Ph.D.

Alex Hughes, Ph.D., will join us in the Spring 2018 semester. Dr. Hughes comes to us from the University of California, San Francisco (UCSF), where he is a postdoctoral fellow. Alex’s research regards determining what he calls the “design rules” underlying how cells assemble into tissues during development, both to better understand these tissues and to engineer methods to build them from scratch

new faculty bugaj
Lukasz Bugaj, Ph.D.

Lukasz Bugaj, Ph.D., will arrive in the Spring 2018 semester. Dr. Bugaj is also coming here from UCSF following a postdoc, and his work is in the field of optogenetics — a scientific process whereby light is used to alter protein conformation, thereby giving one a tool to manipulate cells. In particular, Lukasz’s research has established the ability to induce proteins to cluster ‘on demand’ using light, and he wants to use these and other new technologies he invented to study cell signaling in stem cells and in cancer.

new faculty mitchell
Mike Mitchell, Ph.D.

Mike Mitchell, Ph.D., will also join us in the Spring 2018 semester after finishing his postdoctoral fellowship at MIT in the Langer Lab. In his research, Dr. Mitchell seeks to engineer cells in the bone marrow and blood vessels as a way of gaining control over how and why cancer metastasizes. Mike’s work has already had impressive results in animal models of cancer. His lab will employ tools and concepts from cellular engineering, biomaterials science, and drug delivery to fundamentally understand and therapeutically target complex biological barriers in the body.

In the coming month, we’ll feature podcasts of interview with each of the new faculty members, as well as with Konrad Kording, so be sure to keep an eye out for those.

And to our new faculty, welcome to Penn!